Dyne therapeutics logo
WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. WebMar 2, 2024 · Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39509 36-4883909 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number ...
Dyne therapeutics logo
Did you know?
WebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ... WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ...
WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … WebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they expect the company's stock price to reach $25.83 in the next year. This suggests a possible upside of 175.4% from the stock's current price.
WebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).
WebFeb 9, 2024 · 1 to 50 Employees. Founded: 2024. Type: Company - Public (DYN) Industry: Biotech & Pharmaceuticals. Revenue: Less than $1 million (USD) Competitors: Unknown.
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … highendaudio nlWebSep 17, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18. how fast is 1hzhigh end audio münchenWebApr 13, 2024 · What's Happening With Dyne Therapeutics Inc Stock Today? Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of … high end audio setupWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ... high end audiophile system test musicWebMar 23, 2024 · Dyne Therapeutics sets IPO terms, to offer 10.3 million shares priced at $16 to $18 each. Sep. 10, 2024 at 7:12 a.m. ET by Ciara Linnane. how fast is 1 mile per minuteWebDyne Therapeutics is registered under the ticker NASDAQ:DYN . Their stock opened with $19.00 in its Sep 16, 2024 IPO. Dyne Therapeutics is funded by 9 investors. Logos … how fast is 1 stud per second